Compare Autodesk Inc (ADSK) vs 10X Genomics Inc (TXG) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Autodesk Inc vs 10X Genomics Inc — how do they compare? Autodesk Inc trades at $249.76 (market cap $53.12B), while 10X Genomics Inc trades at $57.54 (market cap $7.61B). The key difference: Autodesk Inc is far larger — about 7× 10X Genomics Inc's market cap, and 10X Genomics Inc is trading nearer its 52-week high, Autodesk Inc nearer its low. Which is the better fit depends on your goals.
| ADSK | TXG | |
|---|---|---|
Market Cap | $53.12B | $7.61B |
Sector | Technology | Health |
52-Week High | $326.79 | $58.57 |
52-Week Low | $187.72 | $11.34 |
Enterprise Value | $52.92B | $7.14B |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Autodesk (ADSK) trades at $256.07, up 2.81% with strong technical momentum and bullish moving averages. The company demonstrates robust fundamentals with revenue growth from $4.4B in 2022 to $6.1B in 2025, net income margin expanding to 19.49%, and consistent earnings beats. Recent news highlights AI investments and upcoming Q2 2027 earnings call on August 27, 2026.
Outlook remains positive with 74.5% analyst buy ratings and $302.23 consensus target offering 18% upside. Key risks include elevated valuation multiples (P/E 36.73) and competitive pressures in design software. The stock's technical strength and fundamental growth trajectory support continued investor interest despite overbought RSI signals.
TXG trades at $58.57, up 12.57% in 24 hours, reflecting strong momentum. The stock is technically bullish with moving averages supporting the uptrend, though RSI levels suggest overbought conditions. Fundamentally, the company shows improving trends with Q2 2026 earnings beating estimates and revenue growth, yet remains unprofitable with a negative net income margin. Recent news highlights collaborations and acquisitions expanding its genomic capabilities.
Outlook is mixed; analyst consensus is neutral with a $46 price target below current levels, indicating caution despite recent beats. Key risks include sustained losses and competitive pressures, but operational cash flow growth and strategic expansions offer potential upside for patient investors focused on long-term biotech innovation.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About Autodesk Inc
Founded in 1982, Autodesk is an application software company that serves industries in architecture, engineering, and construction.
Read more on ADSK →About 10X Genomics Inc
10x Genomics Inc is a life science technology company based in the United States. Its solutions include instruments, consumables, and software for analyzing biological systems. The product portfolio of the company includes Chromium Controller, Reagent Kits, 10x Compatible Products, and Informatics Software among others. The majority of its revenue is generated from consumables.
Read more on TXG →
